Cagrilintide Dosage Chart
Cagrilintide is a long-acting amylin analogue researched as a standalone satiety modulator and as a partner to Semaglutide (CagriSema). Once-weekly subcutaneous administration.
Half-life
~7 days
Format
Injectable
Purity
≥98%
Protocols
4 variants
Research Protocols
Dosage Protocols
Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.
Protocol 1
Titration (Weeks 1-4)
Dose
0.25mg weekly → 0.5mg weekly
Duration
4 weeks
Mirrors the titration schedule seen in Phase 2 trials. Slow escalation reduces initial gastrointestinal adaptation effects.
Protocol 2
Standard Research Protocol
Dose
2.4mg once weekly
Duration
12-20 weeks
Maintenance dose aligned with published cagrilintide monotherapy research. Administered subcutaneously (abdomen, thigh, or upper arm).
Protocol 3
CagriSema Stack Protocol
Dose
Cagrilintide 2.4mg + Semaglutide 2.4mg weekly
Duration
20-24 weeks
Studied stack showing additive effects on body composition markers in early research. Titrate both compounds in parallel.
Protocol 4
Low-Dose Maintenance
Dose
1.2mg weekly
Duration
Ongoing (cycled quarterly)
Reduced research dose for extended exploration. Used post-loading to preserve metabolic signal.
Week by Week
Cagrilintide Titration Schedule
| Week | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 0.25 mg once weekly | Starting rung of the REDEFINE escalation. Deliberately sub-therapeutic to let gastrointestinal tolerance build. |
| Weeks 5-8 | 0.5 mg once weekly | First doubling. Escalation intervals are four weeks throughout, matching the semaglutide-style ladder. |
| Weeks 9-12 | 1.0 mg once weekly | Mid-ladder. Most GI adaptation reported in trials occurs at or before this step. |
| Weeks 13-16 | 1.7 mg once weekly | Final step before maintenance. Held four weeks before the last increase. |
| Week 17 onward | 2.4 mg once weekly | Maintenance dose used in both cagrilintide monotherapy and the CagriSema combination arms. |
Mixing Math
Reconstitution
Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.
Vial size
5mg vial
BAC water
2ml bacteriostatic water
Concentration
2.5mg/ml
Dose / ml
2.4mg ≈ 0.96ml
Syringe units
96 IU on a U-100 insulin syringe
Frequently Paired
Common Stacks
Storage
Handling Notes
Lyophilized powder: -20°C for long-term, 2-8°C for short-term. Once reconstituted, refrigerate at 2-8°C and use within 28 days. Do not freeze reconstituted solution.
Research Considerations
Cautions
- Slow, consistent titration is essential. Rapid escalation amplifies initial GI adaptation.
- Layered with Semaglutide, monitor hydration and electrolytes throughout research.
- Not suitable for lean-mass focused protocols; amylin analogues suppress caloric intake.
Primary Sources
Research Behind This Protocol
Lau 2021 · Lancet
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
PubMed 34798060Garvey 2025 · New England Journal of Medicine
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
PubMed 40544433Davies 2025 · New England Journal of Medicine
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
PubMed 40544432Frias 2023 · Lancet
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes
PubMed 37364590Yamauchi 2026 · Lancet Diabetes & Endocrinology
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity
PubMed 42009015
Ready to start your research
Get Cagrilintide from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy Cagrilintide nowResearch use only. Not medical advice. Browse all dosage charts